Nevertheless, these data might suggest that CCR6+ Th cells are involved in the maintenance of inflammation in ACPA+ RA and may underlie the differences in treatment outcome between ACPA+ and ACPA− RA. This evidence concerns the gene PRTN3 and rheumatoid arthritis.